The FDA has approved Auvelity as the first non-antipsychotic medication specifically cleared to treat agitation in people with Alzheimer’s disease, expanding its earlier approval for major depressive disorder and offering another option for families and clinicians managing difficult behavioral symptoms.
The medication Auvelity, originally cleared for major depressive disorder in adults, now has an additional indication for agitation tied to dementia. Agitation in Alzheimer’s often shows up as excessive movement or verbal and physical aggression, and it can be deeply upsetting for both patients and caregivers. The agency highlighted that agitation can “significantly impact quality of life for patients and caregivers.” This new approval aims to address that burden directly.
The FDA commissioner described the decision as one that “represents a significant advancement in our ability to help patients and families dealing with one of the most challenging aspects of Alzheimer’s disease.” That statement underscores the regulator’s view that this is not just another label change but a meaningful tool for clinicians. The approval follows randomized clinical trials that tested the drug’s effect on real-world behaviors reported by caregivers.
In clinical testing, Auvelity showed benefit in a five-week randomized trial where caregivers tracked how often agitated behaviors occurred. Results from that study found the treatment to be “significantly superior” in improving those behaviors, according to the regulator’s summary. A second trial examined relapse by randomizing responders to continue the medication or switch to placebo, measuring how long it took for agitation to return.
Participants who stayed on Auvelity experienced longer periods before relapse compared with those who were switched to placebo, suggesting the drug can sustain benefit over time. Tracy Beth Hoeg, MD, PhD, acting director of the FDA’s Center for Drug Evaluation and Research, said Auvelity was found to be “efficacious for treating agitation in Alzheimer’s disease” in the trials. That kind of evidence matters because it supports prescribing decisions for a symptom that can be unpredictable and hard to manage.
Auvelity comes as a rapid-onset extended-release tablet, and clinicians are advised to take specific precautions before prescribing. Providers should check blood pressure and screen for any history of bipolar disorder, and they must confirm whether patients are taking other medications that contain bupropion or dextromethorphan. Those steps are intended to reduce risks and spot potential drug interactions before they become a problem.
The FDA listed common side effects such as dizziness, upset stomach, headache, diarrhea, drowsiness, dry mouth, sexual dysfunction and uncontrolled sweating. There are also more serious warnings: the treatment can increase the risk of seizures with higher doses, and it can raise blood pressure or provoke mania in vulnerable individuals. The prescribing information also warns of increased suicidal thoughts in younger adults and urges careful monitoring for the emergence of these behaviors.
CALLOUT: “It is a good choice [over] anti-psychotics in many cases, because it doesn’t cause the same amount of drowsiness or other side effects.”
Experts note that Auvelity acts on two brain targets, NMDA and sigma-1 receptors, which may explain its effect on both agitation and depressive symptoms in older adults with dementia. That dual action is part of why some clinicians see it as an attractive alternative to antipsychotics for certain patients. Compared with older antipsychotic options, many view Auvelity as better tolerated and easier on the heart for very old patients, though it is not without its own risks.
Families and caregivers should discuss this option with treating clinicians, balancing potential benefits against the list of side effects and cautions. Real-world decisions will hinge on each patient’s medical history, current medications and the severity of agitation symptoms. For those struggling with disruptive or dangerous behaviors, this approval offers another evidence-backed choice to explore under medical supervision.
